Cargando…

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53

BACKGROUND: TP53 mutations have a prognostic significance in relapsed and refractory diffuse large B‐cell lymphoma (rrDLBCL) patients, and their treatment still faces a great challenge. This study aimed to evaluate the prognosis of patients with TP53 mutations (TP53mut) in the context of CAR‐T thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Fan, Hu, Kai, Zheng, Peihao, Shi, Hui, Ke, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225230/ https://www.ncbi.nlm.nih.gov/pubmed/36971051 http://dx.doi.org/10.1002/cam4.5756

Ejemplares similares

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Germline mutation in the TP53 gene in uveal melanoma
por: Hajkova, Nikola, et al.
Publicado: (2018)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

TP53 mutations in Romanian patients with colorectal cancer
por: Manirakiza, Felix, et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

Mutational processes shape the landscape of TP53 mutations in human cancer
por: Giacomelli, Andrew O., et al.
Publicado: (2018)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

TP53 allele loss, mutations and expression in malignant melanoma.
por: Flørenes, V. A., et al.
Publicado: (1994)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Number of rare germline CNVs and TP53 mutation types
por: Silva, Amanda G, et al.
Publicado: (2012)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Clinical implications of germline mutations in breast cancer: TP53
por: Schon, Katherine, et al.
Publicado: (2017)

TP53 Mutations Promote Immunogenic Activity in Breast Cancer
por: Liu, Zhixian, et al.
Publicado: (2019)

TP53 mutations, expression and interaction networks in human cancers
por: Wang, Xiaosheng, et al.
Publicado: (2016)

The Brazilian TP53 mutation (R337H) and sarcomas
por: Volc, Sahlua Miguel, et al.
Publicado: (2020)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

The role of TP53 gain-of-function mutation in multifocal glioblastoma
por: Olafson, Lauren R., et al.
Publicado: (2020)

Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upacorcrbjuf83u27807ljld38